 |
|
|
| |
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationship for MK-5172, a Novel Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, in Genotype 1 and Genotype 3 HCV-Infected Patients
|
| |
| |
Reported by Jules Levin
AASLD
Nov 5-8 2011 SF
L. Caro1, M. Anderson1, L. Du1, J. Palcza1, L. Han1, K. Van Dyck2, M. Robberechts2, I. De Lepeleire2, A. Petry1, M.B. Young1, I. Fraser1, E. O'Mara1, V. Moiseev3, Z. Kobalava3, M. Uhle4, F. Wagner 4
Merck Sharp & Dohme Inc., 1Whitehouse Station, NJ and 2Brussels Belgium, 3Russian People's Friendship University, Moscow, Russia, 4Charité Research Organisation GmbH, Berlin, Germany
AASLD: Safety and Antiviral Activity of MK-5172, a Next Generation HCV NS3/4a Protease Inhibitor with a Broad HCV Genotypic Activity Spectrum and Potent Activity Against Known Resistance Mutants, in Genotype 1 and 3 HCV-Infected Patients - (11/07/11)
AASLD: MK-5172, a Second Generation HCV NS3/4A Protease Inhibitor is Active Against Common Resistance Associated Variants (RAVs) and Exhibits Cross-Genotype Activity - (11/07/11)
AASLD: Discovery of MK-4882, a Novel Inhibitor of HCV NS5a with an Attractive Pre-clinical Profile - (11/07/11)
|
| |
|
|
|
|
|
